Nivolumab vs Tirzepatide

## Nivolumab vs Tirzepatide: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Tirzepatide**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Tirzepatide**: Dual GIP and GLP-1 receptor agonist.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Tirzepatide — 5 days.

## Chemical Properties

**Type**: Nivolumab — Antibody; Tirzepatide — Protein.